149 related articles for article (PubMed ID: 15257071)
1. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population.
Potter JM; McWhinney BC; Sampson L; Hickman PE
Ther Drug Monit; 2004 Aug; 26(4):408-14. PubMed ID: 15257071
[TBL] [Abstract][Full Text] [Related]
2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression.
Ratcliffe PJ; Dudley CR; Higgins RM; Firth JD; Smith B; Morris PJ
Lancet; 1996 Sep; 348(9028):643-8. PubMed ID: 8782754
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients.
Bergmann TK; Isbel NM; Barraclough KA; Campbell SB; McWhinney BC; Staatz CE
Clin Drug Investig; 2014 Mar; 34(3):183-8. PubMed ID: 24385281
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
6. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
[TBL] [Abstract][Full Text] [Related]
7. Prednisolone and Prednisone Pharmacokinetics in Pediatric Renal Transplant Recipients-A Prospective Study.
Skauby RH; Bjerre A; Sæves I; Vethe NT; Bremer S; Svarstad A; Bergan S
Ther Drug Monit; 2017 Oct; 39(5):472-482. PubMed ID: 28749817
[TBL] [Abstract][Full Text] [Related]
8. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.
Dantal J; Hourmant M; Cantarovich D; Giral M; Blancho G; Dreno B; Soulillou JP
Lancet; 1998 Feb; 351(9103):623-8. PubMed ID: 9500317
[TBL] [Abstract][Full Text] [Related]
9. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.
Brown JH; Murphy BG; Douglas AF; Short CD; Bhatnagar D; Mackness MI; Hunt LP; Doherty CC; Durrington PN
Nephron; 1997; 75(3):277-82. PubMed ID: 9069448
[TBL] [Abstract][Full Text] [Related]
10. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
Carstens J
Scand J Urol Nephrol; 2008; 42(3):286-92. PubMed ID: 18432535
[TBL] [Abstract][Full Text] [Related]
11. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
12. Prednisone metabolism in recipients of kidney or liver transplants and in lung recipients receiving ketoconazole.
Jeng S; Chanchairujira T; Jusko W; Steiner R
Transplantation; 2003 Mar; 75(6):792-5. PubMed ID: 12660503
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
[TBL] [Abstract][Full Text] [Related]
14. Improving the therapeutic monitoring of cyclosporin A.
Warrens AN; Waters JB; Salama AD; Lechler RI
Clin Transplant; 1999 Apr; 13(2):193-200. PubMed ID: 10202617
[TBL] [Abstract][Full Text] [Related]
15. Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine.
Aleksic I; Baryalei M; Busch T; Pieske B; Schorn B; Strauch J; Sîrbu H; Dalichau H
Transplantation; 2000 Apr; 69(8):1586-90. PubMed ID: 10836367
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
Solari SG; Goldberg LR; DeNofrio D; Shaw LM
Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Park JW; Siekmeier R; Merz M; Krell B; Harder S; März W; Seidel D; Schüler S; Gross W
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):439-50. PubMed ID: 12395976
[TBL] [Abstract][Full Text] [Related]
18. Exposure-effect relationship of mycophenolic acid and prednisolone in adult patients with lupus nephritis.
Abd Rahman AN; Tett SE; Abdul Gafor HA; McWhinney BC; Staatz CE
Br J Clin Pharmacol; 2015 Nov; 80(5):1064-75. PubMed ID: 25959850
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A-induced gingival overgrowth is unrelated to allograft function in renal transplant recipients.
Thomas DW; Baboolal K; Subramanian N; Newcombe RG
J Clin Periodontol; 2001 Jul; 28(7):706-9. PubMed ID: 11422595
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
Kovarik JM; Kahan BD; Kaplan B; Lorber M; Winkler M; Rouilly M; Gerbeau C; Cambon N; Boger R; Rordorf C;
Clin Pharmacol Ther; 2001 Jan; 69(1):48-56. PubMed ID: 11180038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
